Treats symptomatic tenosynovial giant cell tumor (TGCT). Sold as Pimjetmi. Every FDA application for this active ingredient.
As of Nov 21, 2026, FDA lists 1 application for Pimicotinib (sold as Pimjetmi), first approved Nov 10, 2026, with 0 new uses approved and 0 published complete response letters.
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Nov 10, 2026 | PimjetmiNDA 220414 · New molecular entity | EMD Serono | 0 | Marketed |
| Neoadjuvant Pimicotinib Combined With Surgery Versus Upfront Surgery for Diffuse Tenosynovial Giant Cell TumorTenosynovial Giant Cell Tumor, Diffuse · Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 2 | Not yet recruiting | Jul 16, 2026 |
| Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)Tenosynovial Giant Cell Tumor · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Phase 2 | Recruiting | Mar 30, 2026 |
| A Study to Evaluate the Effect of a High-fat Meal on the Exposure of Pimicotinib Capsule in Healthy SubjectsHealthy Subjects · Abbisko Therapeutics Co, Ltd | Phase 1 | Active, not recruiting | Mar 19, 2025 |
| A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)cGvHD · Abbisko Therapeutics Co, Ltd | Phase 2 | Enrolling by invitation | Jan 2, 2024 |
| A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic CancerAdvanced Pancreatic Cancer · Abbisko Therapeutics Co, Ltd | Phase 2 | Recruiting | Nov 1, 2023 |
| Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis · Abbisko Therapeutics Co, Ltd | Phase 3 | Active, not recruiting | Apr 7, 2023 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA